Induced Pluripotent Stem Cells
GPTKB entity
Properties (42)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Stem Cells
|
| gptkbp:built |
Somatic cells
|
| gptkbp:characteristics |
Self-renewal
Pluripotency |
| gptkbp:clinicalTrials |
Ongoing
|
| gptkbp:createdBy |
Reprogramming factors
|
| gptkbp:established |
gptkb:Shinya_Yamanaka
|
| gptkbp:firstClaim |
Cell therapy
Drug discovery Disease modeling Tissue engineering |
| gptkbp:firstDescribedBy |
2006
|
| gptkbp:hasDepartment |
Genetic stability
Efficiency of reprogramming Epigenetic memory Tumorigenicity |
| gptkbp:hasResearchInterest |
Cancer research
Diabetes Cardiovascular diseases Neurodegenerative diseases |
| gptkbp:historicalResearch |
Applications in personalized medicine
Clinical applications development Improving reprogramming techniques Understanding differentiation pathways Gene_editing_technologies |
| https://www.w3.org/2000/01/rdf-schema#label |
Induced Pluripotent Stem Cells
|
| gptkbp:patentCitation |
Numerous patents filed
|
| gptkbp:regulatoryCompliance |
Regulated_by_EMA
Regulated_by_FDA |
| gptkbp:relatedTo |
Embryonic Stem Cells
Adult Stem Cells |
| gptkbp:requires |
Klf4
Oct4 Sox2 c-Myc |
| gptkbp:researchInterest |
gptkb:Harvard_University
gptkb:Stanford_University gptkb:University_of_California gptkb:Kyoto_University |
| gptkbp:sustainabilityInitiatives |
Less than embryonic stem cells
|
| gptkbp:translatedInto |
Any cell type
|
| gptkbp:usedFor |
Regenerative_Medicine
|